Apalutamide Active in Castration - Resistant Prostate Cancer
Apalutamide prolongs metastasis - free survival in non - metastatic castration - resistant prostate cancer
Abstract MicroRNAs (miRNAs) are poised to provide diagnostic, prognostic, and therapeutic targets for several diseases including malignancies for precision medicine applications. The miRNAs have immense potential in the clinical arena because they can be detected in the blood, serum, tissues (fresh and formalin-fixed paraffin-embedded), and fine-needle aspirate specimens. The most attractive feature of miRNA-based therapy is that a single miRNA could be useful for targeting multiple genes that are deregulated in cancers, which can be further investigated through systems biology and network analysis that may provid...
(Wiley) A new study reveals declines in prostate cancer screening and diagnoses in the United States in recent years, as well as decreases in the use of definitive treatments in men who have been diagnosed.
The thumbnail take on finasteride has been that it prevents prostate cancer but increases the risk for high-grade disease. A new study debunks the latter idea.Medscape Medical News
In a novel study, the three leading prostate cancer genomics tests, which are used to help stratify favorable-risk cancers and to aid decision-making about active surveillance, were compared.Medscape Medical News
In this study, chitosan was used to coat the adsorbent for preventing the leakage of Zn2+ loaded. Meanwhile, freeze-drying method was used to enhance adsorption capacity of Zn2+-loaded cellulose beads for testosterone. The results indicate that after the adsorbent was coated by 0.02% chitosan solution, the highest adsorption percentage reached 48%, during adsorption, the Zn2+ concentration in plasma did not increase; the adsorption capacity of the adsorbent can be significantly enhanced by freeze-drying. The results may be caused by porosity of the adsorbent enlarged via freeze-drying and improved stability by coating with...
Conclusions: When AA was administered without goserilin, only 78% achieved castration levels. AA combined with SRT and goserilin did not increase pelvic toxicity, but lead to an unsuspected high frequency of grade 3 liver toxicity. The phase II recommended dose of AA combined to goserelin and SRT is 750 mg. PMID: 29774129 [PubMed]
(SWOG) Twenty five years after it opened for enrollment, the landmark Prostate Cancer Prevention Trial has delivered a final verdict. Finasteride, a common hormone-blocking drug, reduces mens' risk of getting prostate cancer without increasing their risk of dying from the disease.
(MedPage Today) -- Discordance between tests, with NCCN risk criteria
CONCLUSIONS: PER3 can induce sensitivity of paclitaxel-resistant cell lines to paclitaxel by inhibiting the expression of Notch1. PMID: 29771413 [PubMed - in process]